A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.

Abstract

Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin. Eligibility criteria included measurable disease; performance status (SWOG) 0-2; no more than one prior chemotherapeutic regimen; and no prior doxorubicin therapy. The starting esorubicin dosing schedule was 30 mg/m2 every 3 weeks for good risk patients and 25 mg/m2 every 3 weeks for poor risk patients. Twenty-one patients were eligible for evaluation of response and toxicity to treatment. These patients received a median of 3 courses of esorubicin (range 1-13 courses). None of the 21 patients experienced a response to esorubicin. Median survival was 5.5 months. Leukopenia was the major toxicity. Eleven (79%) of the good risk patients and 2 (29%) of the poor risk patients experienced severe to life-threatening leukopenia. Mild to severe anemia was seen in 10 (71%) of the good risk patients and 7 (100%) of the poor risk patients. We conclude that esorubicin is ineffective in the treatment of ovarian cancer patients who have received primary chemotherapy.

• Authors: D S Alberts, N Mason-Liddil, D Stock-Novack, R V O'Toole, T M Abbott, S E Salmon
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 15 Issue 2 Pg. 146-9 (Apr 1992) ISSN: 0277-3732 [Print] United States
• PMID: 1553903 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibiotics, Antineoplastic
• Doxorubicin
• esorubicin

Topics

• Aged
• Antibiotics, Antineoplastic (adverse effects, therapeutic use)
• Carcinoma (drug therapy, secondary)
• Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Middle Aged
• Ovarian Neoplasms (drug therapy, pathology)
• Survival Analysis
• Treatment Outcome